<!DOCTYPE html>
<!--[if lt IE 7]>      <html lang="en-US" class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html lang="en-US" class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html lang="en-US" class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--> <html lang="en-US" class="no-js"> <!--<![endif]-->
    <head>

        <meta http-equiv="X-UA-Compatible" content="IE=edge">
		<meta charset="ISO-8859-1">
        <meta name="viewport" content="width=device-width, initial-scale=1">

        <link rel="stylesheet" href="/assets/css/normalize.min.css">
        <link rel="stylesheet" href="/assets/css/main.css">
        <link rel="stylesheet" href="/assets/css/bootstrap-2.3.2.min.css">
        <link rel="stylesheet" href="/assets/css/oscn-navigation.css?v=1.0.1">
        <link rel="stylesheet" href="/assets/css/oscn-footer.css">
		<link rel="stylesheet" href="/wp-content/themes/oscn-theme/navigation-style.css">
		<link rel="stylesheet" href="https://pro.fontawesome.com/releases/v5.15.4/css/all.css">
		<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/flexboxgrid/6.3.1/flexboxgrid.min.css">
        <!-- <script src="/assets/js/modernizr-2.6.2.min.js"></script> -->
		
		<!--[if lt IE 9]>	
		<script src="/assets/js/respond.min.js"></script>
		<script>
		window.onload = function() {
			setTimeout(function(){				
				var height = $(".footer").outerHeight(true);
				$("#oscn-content").css("padding-bottom", function(){
					return height;
				});}, 2000);
		}
		</script>
		<![endif]-->
        <script src="/assets/js/cookies.js"></script>
<style>.row { margin-left: auto; } </style>		
		<title>Schedule I
</title>
<link rel="stylesheet" href="/assets/css/opinions.css">
<style type="text/css">
blockquote { border: 0 solid black; }
hr { margin: 4px 0;}
#oscn-content a{ text-decoration: underline;}
pre { background: none; border: none;}
@media print {
	#statutes-navigation {
		display: none;
	}
}
@media screen and (min-width: 768px) and (max-width: 1024px) {
    .main-aside-on {
        width: auto!important;
        padding-right: 150px;
    }
}
@media screen and (min-width: 922px) and (max-width: 1280px){
	.main-aside-on {
		width: 992px!important;
	}
}

@media screen and (min-width: 1280px) { 
	.main-aside-on { width: 1280px!important; padding-right: 150px;}
} 
</style>

		<script src="/datafiles/ext/javascript-navigation/?v=1.0.0" type="text/javascript"></script>
	</head>
    <body>
	<div class="wrapper">
		<header id="masthead" class="site-header" data-elastic-exclude style="">
		<div class="nav_container">
				<a class="oscn-brand" href="https://www.oscn.net/">
					<div class="oscn-brand-container">
						<div class="oscn-logo"><img src="https://www.oscn.net/static/supreme-court-seal-updated-color.svg"></div>
						<div class="oscn-full-name"><span>OKLAHOMA <br>STATE <br>COURTS <br>NETWORK </span></div>
						<div class="oscn-abbreviation"><span>OSCN</span></div>
					</div>
				</a>
		</div>
	</header><!-- #masthead -->	
	<div id="oscn-content">
		<div class="container-fluid sized"><img style='position: absolute;' src='/applications/oscn/images/_STATUTE.gif?dbcode=STOKST63&citeid=98866'/><title>OSCN Found Document:Schedule I
</title>
<SCRIPT>
var listorder='1816000';
var CiteID='98866';
var dbCode='STOKST63&year=';

function GetPrevious(){window.location.href='deliverdocument.asp?lookup=Previous&listorder='+listorder+'&dbCode='+dbCode;}
function GetNext(){window.location.href='deliverdocument.asp?lookup=Next&listorder='+listorder+'&dbCode='+dbCode;}
function GetIndex(){window.location.href='index.asp?level=1&ftdb='+dbCode;}
function GetHereInIndex(){window.location.href='index.asp?level=1&ftdb='+dbCode+'#CiteID'+CiteID;}
function GetCitationize(){window.location.href='citationize.asp?citeid='+CiteID;}
function PrintOnly(){window.location.href='deliverdocument.asp?citeid='+CiteID+'&PrintOnly=true';}
function ordinal_suffix_of(i) {
    var j = i % 10,
        k = i % 100;
    if (j == 1 && k != 11) {
        return i + "st";
    }
    if (j == 2 && k != 12) {
        return i + "nd";
    }
    if (j == 3 && k != 13) {
        return i + "rd";
    }
    return i + "th";
}
</SCRIPT>
				<div id="statutes-navigation" style="clear: both; background-color: #0073cf; border-bottom: 1px solid white; font-family: Arial; font-size: 10pt; min-width: 588px; width: 100%; float: left; font-weight: bold; ">
					<div class="container-fluid sized">
					<ol style="list-style: none; padding: 0px; margin: 0px; background-color: #0073cf; float: left;">
						<li style="display: inline; float: left;">
						<a style="text-decoration: none; color: white; display: block; border-left: solid 1px white; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:GetPrevious();">Previous Section</a></li>

						<li style="display: inline; float: left;">
						<a style="text-decoration: none; color: white; display: block; padding: 5px; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:GetIndex();">Top Of Index</a></li>

						<li style="display: inline; float: left;">
						<a style="text-decoration: none; color: white; display: block; padding: 5px; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:GetHereInIndex();">This Point in Index</a></li>

						<li style="display: inline; float: left;">
						<a style="text-decoration: none; color: white; display: block; padding: 5px; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:GetCitationize();">Citationize</a></li>

						<li style="display: inline; float: left;">
						<a style="text-decoration: none; color: white; display: block; padding: 5px; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:GetNext();">Next Section</a></li>

						<li class="tmp-hide-print" style="float: left;">
						<a style="text-decoration: none; color: white; display: block; padding: 5px; border-right: solid 1px white; padding: 2px 8px;"
							 href="javascript:PrintOnly();">Print Only</a></li>
					</ol>
					</div>
				</div>
			<div id="statutes-title" style="clear: both; background-color: #0073cf; font-family: Arial; font-size: 10pt;width: 100%; font-weight: bold; color: white; text-align: center; ">
			<div class="container-fluid sized">
Title 63. Public Health and Safety
			</div></div>
				
	<script>
	var a = document.getElementById("statutes-navigation");
	var b = document.getElementsByClassName("header");
	var c = document.getElementById("statutes-title");
    b[0].appendChild(a);
    b[0].appendChild(c);


</script>			

<div class="document_header">
<P ALIGN=LEFT><STRONG><a href="/applications/OCISWeb/index.asp?level=1&ftdb=STOKST"><img src="/Images/Applications/search/WDFolderOpen.gif" border=0></a><FONT FACE=ARIAL SIZE=4>Oklahoma Statutes Citationized</FONT><BR><FONT FACE=ARIAL SIZE=3>&nbsp;&nbsp;<a href="/applications/OCISWeb/index.asp?level=1&ftdb=STOKST63"><img src="/Images/Applications/search/WDFolderOpen.gif" border=0></a>Title 63. Public Health and Safety
<BR><FONT FACE=ARIAL SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;<a href="/applications/OCISWeb/index.asp?level=1&ftdb=STOKST63#Chapter2-UniformControlledDangerousSubstancesAct"><img src="/Images/Applications/search/WDFolderOpen.gif" border=0></a>Chapter 2 - Uniform Controlled Dangerous Substances Act<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="/applications/OCISWeb/index.asp?level=1&ftdb=STOKST63#Article2-StandardsandSchedules"><img src="/Images/Applications/search/WDFolderOpen.gif" border=0></a>Article Article 2 - Standards and Schedules<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="/Images/Applications/search/WDDocument.gif">Section&nbsp;2-204 - Schedule I<BR>
</STRONG>
<FONT SIZE=1>Cite as: 63 O.S. § 2-204 (OSCN 2025)</FONT><HR>

</div>
<p>The controlled substances listed in this section are included in Schedule I and include any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, when the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation.</p>

<p>A. Any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, when the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:</p>

<p>1. Acetylmethadol;</p>

<p>2. Allylprodine;</p>

<p>3. Alphacetylmethadol;</p>

<p>4. Alphameprodine;</p>

<p>5. Alphamethadol;</p>

<p>6. Benzethidine;</p>

<p>7. Betacetylmethadol;</p>

<p>8. Betameprodine;</p>

<p>9. Betamethadol;</p>

<p>10. Betaprodine;</p>

<p>11. Clonitazene;</p>

<p>12. Dextromoramide;</p>

<p>13. Dextrorphan (except its methyl ether);</p>

<p>14. Diampromide;</p>

<p>15. Diethylthiambutene;</p>

<p>16. Dimenoxadol;</p>

<p>17. Dimepheptanol;</p>

<p>18. Dimethylthiambutene;</p>

<p>19. Dioxaphetyl butyrate;</p>

<p>20. Dipipanone;</p>

<p>21. Ethylmethylthiambutene;</p>

<p>22. Etonitazene;</p>

<p>23. Etoxeridine;</p>

<p>24. Furethidine;</p>

<p>25. Hydroxypethidine;</p>

<p>26. Isotonitazene;</p>

<p>27. Ketobemidone;</p>

<p>28. Levomoramide;</p>

<p>29. Levophenacylmorphan;</p>

<p>30. Metonitazene;</p>

<p>31. Morpheridine;</p>

<p>32. N-desethyl isotonitazene;</p>

<p>33. N-pyrrolidino protonitazene;</p>

<p>34. Noracymethadol;</p>

<p>35. Norlevorphanol;</p>

<p>36. Normethadone;</p>

<p>37. Norpipanone;</p>

<p>38. Phenadoxone;</p>

<p>39. Phenampromide;</p>

<p>40. Phenomorphan;</p>

<p>41. Phenoperidine;</p>

<p>42. Piritramide;</p>

<p>43. Proheptazine;</p>

<p>44. Properidine;</p>

<p>45. Protonitazene;</p>

<p>46. Racemoramide; or</p>

<p>47. Trimeperidine.</p>

<p>B. Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>

<p>1. Acetorphine;</p>

<p>2. Acetyldihydrocodeine;</p>

<p>3. Benzylmorphine;</p>

<p>4. Codeine methylbromide;</p>

<p>5. Codeine-N-Oxide;</p>

<p>6. Cyprenorphine;</p>

<p>7. Desomorphine;</p>

<p>8. Dihydromorphine;</p>

<p>9. Etorphine;</p>

<p>10. Heroin;</p>

<p>11. Hydromorphinol;</p>

<p>12. Methyldesorphine;</p>

<p>13. Methylhydromorphine;</p>

<p>14. Morphine methylbromide;</p>

<p>15. Morphine methylsulfonate;</p>

<p>16. Morphine-N-Oxide;</p>

<p>17. Myrophine;</p>

<p>18. Nicocodeine;</p>

<p>19. Nicomorphine;</p>

<p>20. Normorphine;</p>

<p>21. Phoclodine;</p>

<p>22. Thebacon;</p>

<p>23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (Acetyl fentanyl);</p>

<p>24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide (Crotonyl fentanyl);</p>

<p>25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide (Furanyl fentanyl);</p>

<p>26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);</p>

<p>27. N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or</p>

<p>28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (Butyrl fentanyl).</p>

<p>C. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>

<p>1. Methcathinone;</p>

<p>2. 3, 4-methylenedioxy amphetamine;</p>

<p>3. 3, 4-methylenedioxy methamphetamine;</p>

<p>4. 5-methoxy-3, 4-methylenedioxy amphetamine;</p>

<p>5. 3, 4, 5-trimethoxy amphetamine;</p>

<p>6. Bufotenine;</p>

<p>7. Diethyltryptamine;</p>

<p>8. Dimethyltryptamine;</p>

<p>9. 4-methyl-2, 5-dimethoxyamphetamine;</p>

<p>10. Ibogaine;</p>

<p>11. Lysergic acid diethylamide;</p>

<p>12. Marijuana;</p>

<p>13. Mescaline;</p>

<p>14. N-benzylpiperazine;</p>

<p>15. N-ethyl-3-piperidyl benzilate;</p>

<p>16. N-methyl-3-piperidyl benzilate;</p>

<p>17. Psilocybin;</p>

<p>18. Psilocyn;</p>

<p>19. 2, 5 dimethoxyamphetamine;</p>

<p>20. 4 Bromo-2, 5-dimethoxyamphetamine;</p>

<p>21. 4 methoxyamphetamine;</p>

<p>22. Cyclohexamine;</p>

<p>23. Salvia Divinorum;</p>

<p>24. Salvinorin A;</p>

<p>25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine; TPCP, TCP;</p>

<p>26. Phencyclidine (PCP);</p>

<p>27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;</p>

<p>28. 1-(3-trifluoromethylphenyl) piperazine;</p>

<p>29. Flunitrazepam;</p>

<p>30. B-hydroxy-amphetamine;</p>

<p>31. B-ketoamphetamine;</p>

<p>32. 2,5-dimethoxy-4-nitroamphetamine;</p>

<p>33. 2,5-dimethoxy-4-bromophenethylamine;</p>

<p>34. 2,5-dimethoxy-4-chlorophenethylamine;</p>

<p>35. 2,5-dimethoxy-4-iodoamphetamine;</p>

<p>36. 2,5-dimethoxy-4-iodophenethylamine;</p>

<p>37. 2,5-dimethoxy-4-methylphenethylamine;</p>

<p>38. 2,5-dimethoxy-4-ethylphenethylamine;</p>

<p>39. 2,5-dimethoxy-4-fluorophenethylamine;</p>

<p>40. 2,5-dimethoxy-4-nitrophenethylamine;</p>

<p>41. 2,5-dimethoxy-4-ethylthio-phenethylamine;</p>

<p>42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;</p>

<p>43. 2,5-dimethoxy-4-propylthio-phenethylamine;</p>

<p>44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;</p>

<p>45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;</p>

<p>46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;</p>

<p>47. 5-methoxy-N, N-dimethyltryptamine;</p>

<p>48. N-methyltryptamine;</p>

<p>49. A-ethyltryptamine;</p>

<p>50. A-methyltryptamine;</p>

<p>51. N, N-diethyltryptamine;</p>

<p>52. N, N-diisopropyltryptamine;</p>

<p>53. N, N-dipropyltryptamine;</p>

<p>54. 5-methoxy-a-methyltryptamine;</p>

<p>55. 4-hydroxy-N, N-diethyltryptamine;</p>

<p>56. 4-hydroxy-N, N-diisopropyltryptamine;</p>

<p>57. 5-methoxy-N, N-diisopropyltryptamine;</p>

<p>58. 4-hydroxy-N-isopropyl-N-methyltryptamine;</p>

<p>59. 3,4-Methylenedioxymethcathinone (Methylone);</p>

<p>60. 3,4-Methylenedioxypyrovalerone (MDPV);</p>

<p>61. 3-Methylmethcathinone (Metaphedrone);</p>

<p>62. 4-Methylmethcathinone (Mephedrone);</p>

<p>63. 4-methoxymethcathinone;</p>

<p>64. 4-Fluoromethcathinone;</p>

<p>65. 3-Fluoromethcathinone;</p>

<p>66. 1-(8-bromobenzo 1,2-b;4,5-b difuran-4-yl)-2-aminopropane;</p>

<p>67. 2,5-Dimethoxy-4-chloroamphetamine;</p>

<p>68. 4-Methylethcathinone;</p>

<p>69. Pyrovalerone;</p>

<p>70. N,N-diallyl-5-methoxytryptamine;</p>

<p>71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);</p>

<p>72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);</p>

<p>73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);</p>

<p>74. Alpha-Pyrrolidinopentiophenone;</p>

<p>75. 4-Fluoroamphetamine;</p>

<p>76. Pentedrone;</p>

<p>77. 4-Methyl-a-pyrrolidinohexaphenone;</p>

<p>78. 2,5-dimethoxy-4-(n)-propylphenethylamine;</p>

<p>79. 2,5-dimethoxyphenethylamine;</p>

<p>80. 1,4-Dibenzylpiperazine;</p>

<p>81. N,N-Dimethylamphetamine;</p>

<p>82. 4-Fluoromethamphetamine;</p>

<p>83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25C-NBOMe);</p>

<p>84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe);</p>

<p>85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine (25B-NBOMe);</p>

<p>86. 1-(4-Fluorophenyl)piperazine;</p>

<p>87. Methoxetamine;</p>

<p>88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-methylbenzamide;</p>

<p>89. N-ethyl hexadrone;</p>

<p>90. Isopropyl-U-47700;</p>

<p>91. Para-fluorobutyrl fentanyl;</p>

<p>92. Para-fluorofentanyl (pFF);</p>

<p>93. Fluoro isobutryrl fentanyl;</p>

<p>94. 3-Hydroxy Phencyclidine (PCP);</p>

<p>95. 3-methoxy Phencyclidine (PCP);</p>

<p>96. Flualprazolam; or</p>

<p>97. Flubromazolam.</p>

<p>D. Unless specifically excepted or unless listed in a different schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant or depressant effect on the central nervous system:</p>

<p>1. Fenethylline;</p>

<p>2. Mecloqualone;</p>

<p>3. N-ethylamphetamine;</p>

<p>4. Methaqualone;</p>

<p>5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium oxybate, and sodium oxybutyrate;</p>

<p>6. Gamma-Butyrolactone (GBL) as packaged, marketed, manufactured or promoted for human consumption, with the exception of legitimate food additive and manufacturing purposes;</p>

<p>7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes;</p>

<p>8. Gamma Valerolactone (GVL) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes;</p>

<p>9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception of legitimate manufacturing purposes; or</p>

<p>10. N-ethylpentylone.</p>

<p>E. 1. The following industrial uses of Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are excluded from all schedules of controlled substances under this title:</p>

<p>a. pesticides,</p>

<p>b. photochemical etching,</p>

<p>c. electrolytes of small batteries or capacitors,</p>

<p>d. viscosity modifiers in polyurethane,</p>

<p>e. surface etching of metal coated plastics,</p>

<p>f. organic paint disbursements for water soluble inks,</p>

<p>g. pH regulators in the dyeing of wool and polyamide fibers,</p>

<p>h. foundry chemistry as a catalyst during curing,</p>

<p>i. curing agents in many coating systems based on urethanes and amides,</p>

<p>j. additives and flavoring agents in food, confectionary, and beverage products,</p>

<p>k. synthetic fiber and clothing production,</p>

<p>l. tetrahydrofuran production,</p>

<p>m. gamma butyrolactone production,</p>

<p>n. polybutylene terephthalate resin production,</p>

<p>o. polyester raw materials for polyurethane elastomers and foams,</p>

<p>p. coating resin raw material, and</p>

<p>q. as an intermediate in the manufacture of other chemicals and pharmaceuticals.</p>

<p>2. At the request of any person, the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control may exempt any other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol from being included as a Schedule I controlled substance if such product is labeled, marketed, manufactured and distributed for legitimate industrial use in a manner that reduces or eliminates the likelihood of abuse.</p>

<p>3. In making a determination regarding an industrial product, the Director, after notice and hearing, shall consider the following:</p>

<p>a. the history and current pattern of abuse,</p>

<p>b. the name and labeling of the product,</p>

<p>c. the intended manner of distribution, advertising and promotion of the product, and</p>

<p>d. other factors as may be relevant to and consistent with the public health and safety.</p>

<p>4. The hearing shall be held in accordance with the procedures of the Administrative Procedures Act.</p>

<p>F. Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>

<p>1. JWH-004;</p>

<p>2. JWH-007;</p>

<p>3. JWH-009;</p>

<p>4. JWH-015;</p>

<p>5. JWH-016;</p>

<p>6. JWH-018;</p>

<p>7. JWH-019;</p>

<p>8. JWH-020;</p>

<p>9. JWH-030;</p>

<p>10. JWH-046;</p>

<p>11. JWH-047;</p>

<p>12. JWH-048;</p>

<p>13. JWH-049;</p>

<p>14. JWH-050;</p>

<p>15. JWH-070;</p>

<p>16. JWH-071;</p>

<p>17. JWH-072;</p>

<p>18. JWH-073;</p>

<p>19. JWH-076;</p>

<p>20. JWH-079;</p>

<p>21. JWH-080;</p>

<p>22. JWH-081;</p>

<p>23. JWH-082;</p>

<p>24. JWH-094;</p>

<p>25. JWH-096;</p>

<p>26. JWH-098;</p>

<p>27. JWH-116;</p>

<p>28. JWH-120;</p>

<p>29. JWH-122;</p>

<p>30. JWH-145;</p>

<p>31. JWH-146;</p>

<p>32. JWH-147;</p>

<p>33. JWH-148;</p>

<p>34. JWH-149;</p>

<p>35. JWH-150;</p>

<p>36. JWH-156;</p>

<p>37. JWH-167;</p>

<p>38. JWH-175;</p>

<p>39. JWH-180;</p>

<p>40. JWH-181;</p>

<p>41. JWH-182;</p>

<p>42. JWH-184;</p>

<p>43. JWH-185;</p>

<p>44. JWH-189;</p>

<p>45. JWH-192;</p>

<p>46. JWH-193;</p>

<p>47. JWH-194;</p>

<p>48. JWH-195;</p>

<p>49. JWH-196;</p>

<p>50. JWH-197;</p>

<p>51. JWH-198;</p>

<p>52. JWH-199;</p>

<p>53. JWH-200;</p>

<p>54. JWH-201;</p>

<p>55. JWH-202;</p>

<p>56. JWH-203;</p>

<p>57. JWH-204;</p>

<p>58. JWH-205;</p>

<p>59. JWH-206;</p>

<p>60. JWH-207;</p>

<p>61. JWH-208;</p>

<p>62. JWH-209;</p>

<p>63. JWH-210;</p>

<p>64. JWH-211;</p>

<p>65. JWH-212;</p>

<p>66. JWH-213;</p>

<p>67. JWH-234;</p>

<p>68. JWH-235;</p>

<p>69. JWH-236;</p>

<p>70. JWH-237;</p>

<p>71. JWH-239;</p>

<p>72. JWH-240;</p>

<p>73. JWH-241;</p>

<p>74. JWH-242;</p>

<p>75. JWH-243;</p>

<p>76. JWH-244;</p>

<p>77. JWH-245;</p>

<p>78. JWH-246;</p>

<p>79. JWH-248;</p>

<p>80. JWH-249;</p>

<p>81. JWH-250;</p>

<p>82. JWH-251;</p>

<p>83. JWH-252;</p>

<p>84. JWH-253;</p>

<p>85. JWH-262;</p>

<p>86. JWH-292;</p>

<p>87. JWH-293;</p>

<p>88. JWH-302;</p>

<p>89. JWH-303;</p>

<p>90. JWH-304;</p>

<p>91. JWH-305;</p>

<p>92. JWH-306;</p>

<p>93. JWH-307;</p>

<p>94. JWH-308;</p>

<p>95. JWH-311;</p>

<p>96. JWH-312;</p>

<p>97. JWH-313;</p>

<p>98. JWH-314;</p>

<p>99. JWH-315;</p>

<p>100. JWH-316;</p>

<p>101. JWH-346;</p>

<p>102. JWH-348;</p>

<p>103. JWH-363;</p>

<p>104. JWH-364;</p>

<p>105. JWH-365;</p>

<p>106. JWH-367;</p>

<p>107. JWH-368;</p>

<p>108. JWH-369;</p>

<p>109. JWH-370;</p>

<p>110. JWH-371;</p>

<p>111. JWH-373;</p>

<p>112. JWH-386;</p>

<p>113. JWH-387;</p>

<p>114. JWH-392;</p>

<p>115. JWH-394;</p>

<p>116. JWH-395;</p>

<p>117. JWH-397;</p>

<p>118. JWH-398;</p>

<p>119. JWH-399;</p>

<p>120. JWH-400;</p>

<p>121. JWH-412;</p>

<p>122. JWH-413;</p>

<p>123. JWH-414;</p>

<p>124. JWH-415;</p>

<p>125. CP-55, 940;</p>

<p>126. CP-47, 497;</p>

<p>127. HU-210;</p>

<p>128. HU-211;</p>

<p>129. WIN-55, 212-2;</p>

<p>130. AM-2201;</p>

<p>131. AM-2233;</p>

<p>132. JWH-018 adamantyl-carboxamide;</p>

<p>133. AKB48;</p>

<p>134. JWH-122 N-(4-pentenyl)analog;</p>

<p>135. MAM2201;</p>

<p>136. URB597;</p>

<p>137. URB602;</p>

<p>138. URB754;</p>

<p>139. UR144;</p>

<p>140. XLR11;</p>

<p>141. A-796,260;</p>

<p>142. STS-135;</p>

<p>143. AB-FUBINACA;</p>

<p>144. AB-PINACA;</p>

<p>145. PB-22;</p>

<p>146. AKB48 N-5-Fluorpentyl;</p>

<p>147. AM1248;</p>

<p>148. FUB-PB-22;</p>

<p>149. ADB-FUBINACA;</p>

<p>150. BB-22;</p>

<p>151. 5-Fluoro PB-22; or</p>

<p>152. 5-Fluoro AKB-48.</p>

<p>G. In addition to those substances listed in subsection F of this section, unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups:</p>

<p>1. Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthoylindoles include, but are not limited to:</p>

<p>a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200),</p>

<p>b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),</p>

<p>c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),</p>

<p>d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),</p>

<p>e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),</p>

<p>f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),</p>

<p>g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),</p>

<p>h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),</p>

<p>i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),</p>

<p>j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),</p>

<p>k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),</p>

<p>l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),</p>

<p>m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole (JWH-098),</p>

<p>n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),</p>

<p>o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)indole (AM-1220),</p>

<p>p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201), or</p>

<p>q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);</p>

<p>2. Naphthylmethylindoles: any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthylmethylindoles include, but are not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);</p>

<p>3. Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole structure with or without substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the pyrrole ring to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthoylpyrroles include, but are not limited to:</p>

<p>a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),</p>

<p>b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole (JWH-370),</p>

<p>c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or</p>

<p>d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);</p>

<p>4. Naphthylideneindenes: any compound containing a 1-(1-naphthylmethylene)indene structure with or without substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indene group to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthylmethylindenes include, but are not limited to, (1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176);</p>

<p>5. Phenylacetylindoles: any compound containing a 3-phenylacetylindole structure with or without substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl ring to any extent. Phenylacetylindoles include, but are not limited to:</p>

<p>a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),</p>

<p>b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8),</p>

<p>c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),</p>

<p>d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),</p>

<p>e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or</p>

<p>f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);</p>

<p>6. Cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with or without substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, and whether or not further substituted on the cyclohexyl ring to any extent. Cyclohexylphenols include, but are not limited to:</p>

<p>a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497),</p>

<p>b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue), or</p>

<p>c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);</p>

<p>7. Benzoylindoles: any compound containing a 3-(benzoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl group to any extent. Benzoylindoles include, but are not limited to:</p>

<p>a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),</p>

<p>b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole (Pravadoline or WIN 48, 098),</p>

<p>c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),</p>

<p>d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or</p>

<p>e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole (AM-2233);</p>

<p>8. Cyclopropoylindoles: Any compound containing a 3-(cyclopropoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the cyclopropoyl ring to any extent. Cyclopropoylindoles include, but are not limited to:</p>

<p>a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole (UR-144),</p>

<p>b. 1-(5-chloropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole (5Cl-UR-144), or</p>

<p>c. 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole (XLR11);</p>

<p>9. Indole Amides: Any compound containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole Amides include, but are not limited to:</p>

<p>a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (2NE1),</p>

<p>b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-carboxamide (STS-135),</p>

<p>c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA),</p>

<p>d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),</p>

<p>e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (NNE1),</p>

<p>f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide (5F-NNE1),</p>

<p>g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), or</p>

<p>h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006);</p>

<p>10. Indole Esters: Any compound containing a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to:</p>

<p>a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22),</p>

<p>b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22),</p>

<p>c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22),</p>

<p>d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22), or</p>

<p>e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201);</p>

<p>11. Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to:</p>

<p>a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone (AM1248), or</p>

<p>b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-001);</p>

<p>12. Carbazole Ketone: Any compound containing (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018);</p>

<p>13. Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include, but are not limited to:</p>

<p>a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-l)methanone (JWH-018 benzimidazole analog), or</p>

<p>b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA); and</p>

<p>14. Modified by Replacement: any compound defined in this subsection that is modified by replacement of a carbon with nitrogen in the indole, naphthyl, indene, benzimidazole, or carbazole ring.</p>

<p>H. Any prescription drug approved by the federal Food and Drug Administration under the provisions of Section 505 of the Federal Food, Drug and Cosmetic Act, Title 21 of the United States Code, Section 355, that is designated, rescheduled or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I and shall be prescribed, distributed, dispensed or used in accordance with federal law upon the issuance of a notice, final rule or interim final rule by the United States Drug Enforcement Administration designating, rescheduling or deleting as a controlled substance such a drug product under federal law, unless and until the State Board of Pharmacy takes action pursuant to <a href="DeliverDocument.asp?CiteID=98863">Section 2-201</a> of this title. If the Board of Pharmacy does not take action pursuant to Section 2-201 of this title, the drug product shall be deemed to be designated, rescheduled or deleted as a controlled substance in accordance with federal law and in compliance with the Uniform Controlled Dangerous Substances Act.</p>

<p><b><i>Historical Data</i></b></p>

<hr />
<p>Laws 1971, HB 1100, c. 119, § 2-204; Amended by Laws 1976, SB 737, c. 291, § 1, emerg. eff. June 17, 1976; Amended by Laws 1978, SB 18, c. 194, § 3, emerg. eff. April 14, 1978; Amended by Laws 1984, HB 1231, c. 127, § 1, eff. November 1, 1984; Amended by Laws 1987, HB 1315, c. 138, § 3, emerg. eff. June 19, 1987; Amended by Laws 1994, HB 1916, c. 140, § 1, eff. September 1, 1994; Amended by Laws 1995, SB 354, c. 54, § 2, emerg. eff. July 1, 1995; Amended by Laws 1998, HB 2654, c. 100, § 1, emerg. eff. April 13, 1998 (<a href="/datafiles/superseded/oklahoma/statutes/title63/X130498X63%20OS%202-204.html">superseded document available</a>); Amended by Laws 2000, SB 1467, c. 16, § 1, emerg. eff. April 3, 2000 (<a href="DeliverDocument.asp?citeid=445666">superseded document available</a>); Amended by Laws 2001, SB 441, c. 99, § 2, emerg. eff. July 1, 2001 (<a href="DeliverDocument.asp?citeid=213838">superseded document available</a>); Amended by Laws 2001, HB 1615, c. 373, § 2, emerg. eff. July 1, 2001 (<a href="DeliverDocument.asp?citeid=264385">superseded document available</a>); Amended by Laws 2005, HB 1288, c. 283, § 1, eff. November 1, 2005 (<a href="DeliverDocument.asp?citeid=443785">superseded document available</a>); Amended by Laws 2008, HB 3148, c. 332, § 1, eff. November 1, 2008 (<a href="DeliverDocument.asp?citeid=453127">superseded document available</a>); Amended by Laws 2010, HB 3241, c. 182, § 1, eff. November 1, 2010 (<a href="DeliverDocument.asp?citeid=460563">superseded document available</a>); Amended by Laws 2011, SB 919, c. 239, § 2, eff. November 1, 2011 (<a href="DeliverDocument.asp?citeid=463733">superseded document available</a>); Amended by Laws 2012, HB 2942, c. 80, § 2, eff. November 1, 2012 (<a href="DeliverDocument.asp?citeid=467344">superseded document available</a>); Amended by Laws 2013, HB 2217, c. 181, § 1, eff. November 1, 2013 (<a href="DeliverDocument.asp?citeid=470699">superseded document available</a>); Amended by Laws 2014, HB 2666, c. 154, § 2, eff. November 1, 2014 (<a href="DeliverDocument.asp?citeid=474234">superseded document available</a>); Amended by Laws 2015, HB 1616, c. 305, § 3 (<a href="DeliverDocument.asp?citeid=476555">superseded document available</a>); Amended by Laws 2017, SB 770, c. 390, § 2, emerg. eff. June 6, 2017 (<a href="DeliverDocument.asp?citeid=481338">superseded document available</a>); Amended by Laws 2018, SB 940, c. 134, § 1, eff. November 1, 2018 (<a href="DeliverDocument.asp?citeid=482888">superseded document available</a>); Amended by Laws 2019, SB 166, c. 207, § 1, eff. November 1, 2019 (<a href="DeliverDocument.asp?citeid=485039">superseded document available</a>); Amended by Laws 2021, HB 2656, c. 222, § 2, eff. November 1, 2021 (<a href="DeliverDocument.asp?CiteID=489433">superseded document available</a>); Amended by Laws 2022, SB 1152, c. 70, § 1, eff. November 1, 2022 (<a href="DeliverDocument.asp?CiteID=491243">superseded document available</a>); Amended by Laws 2023, SB 452, c. 120, § 1, eff. November 1, 2023 (<a href="DeliverDocument.asp?CiteID=494835">superseded document available</a>); Amended by Laws 2024, HB 3567, c. 308, § 3, emerg. eff. May 15, 2024 (<a href="DeliverDocument.asp?CiteID=495908">superseded document available</a>).</p>



<!--END DOCUMENT-->
<script>
	var forEach = function (array, callback, scope) {
	  for (var i = 0; i < array.length; i++) {
		callback.call(scope, i, array[i]); // passes back stuff we need
	  }
	};
	//LINKING BILLS
	var db,year,chamber,bill,session,legislative_year,ordinal;
	var re = /\[(HB|SB)\s+(.*?)\]/gi
	
	db = dbCode.split('&')[0];
	if(db.indexOf('STOKLG')>=0){
		year = parseInt(dbCode.split('year=')[1]);
		if(year >= 2003){
			//IE 54th Legislative Session
			legislative_year = Math.floor((year - 1905)/2);
			ordinal = ordinal_suffix_of(legislative_year);
			if(year % 2 ==0) { session = '2R' } else { session = '1R' }

			//chamber (SB|HB) and Bill #
			var results = re.exec(document.title);
			chamber = results[1];
			bill = results[2];
			
			//check for extra sessions
			var header = document.querySelectorAll('.document_header a');
			if(header.length >= 3){
				if(header[header.length -1].href.indexOf('FirstExtraordinarySession') > -1){
					console.log("first");
					session = '1S'
				}else if(header[header.length -1].href.indexOf('SecondExtraordinarySession') > -1) {
					console.log("second");				
					session = '2S'
				}
			}
			
			//build link
			var array = ["https://www.sos.ok.gov","documents","legislation",ordinal,year,session,chamber,bill+'.pdf']
			console.log(array.join('/'));			
		}
		if(year >= 2016 && year <= 2017){
			var a = document.querySelectorAll('a[href*="datafiles"]');
			forEach(a,function(i,el){
				el.parentNode.removeChild(el);
			});
			var hr = document.querySelectorAll('hr')[1]
			hr.parentNode.removeChild(hr);
		}
		if(year >= 2003){
			var text = '<font face="Arial" size="2"><img alt="PDF Document" hspace="0" src="http://www.oscn.net/static/adr/images/PDF_icon.png" align="baseline" border="0"><br>PDF of Session Law from <br>the Oklahoma Secretary of State</font>'
			var para = '<p style="text-align: center;"></p>';
			var link = document.createElement('a');
			link.setAttribute('href',array.join('/'));
			link.innerHTML = text;
			para = document.createElement('p');
			para.setAttribute('style','text-align: center;');
			para.appendChild(link);
			var hr = document.createElement("hr");
			header = document.querySelectorAll(".document_header")[0];
			header.parentNode.insertBefore(hr, header.nextSibling);			
			header.parentNode.insertBefore(para, header.nextSibling);			
		}
		if(year <= 1995){
			//chamber (SB|HB) and Bill #
			var results = re.exec(document.title);
			chamber = results[1];
			bill = results[2];
			url = '/datafiles/session-laws/'+year + '/' + chamber + '-' + bill + '.pdf';
			
			var para = '<p style="text-align: center;"><font face="Arial" size="2"><img alt="PDF Document" hspace="0" src="http://www.oscn.net/static/adr/images/PDF_icon.png" align="baseline" border="0"></font><br /><a href="'+url+'">PDF of Session Law</a></p><p><i>*Document and scanned images are provided for research purposes only. Please refer to the print material for accuracy.</i></p><hr />';
			var element = document.createElement('p');
			var header = document.querySelectorAll(".document_header")[0];
			header.parentNode.insertBefore(element, header.nextSibling);
			element.outerHTML = para;
		}
	}
</script>
<FONT FACE=ARIAL SIZE=2><B><EM>Citationizer<SUP>©</SUP> Summary of Documents Citing This Document<HR>
</B><FONT FACE=ARIAL SIZE=1>
<TABLE>
<THEAD>
	<TH ALIGN=LEFT><FONT SIZE=1>Cite</FONT></TH>
	<TH ALIGN=LEFT><FONT SIZE=1>Name</FONT></TH>
	<TH ALIGN=LEFT><FONT SIZE=1>Level</FONT></TH>
</THEAD>
<TBODY>
<tr><td colspan="4"><font size="1"><strong>Oklahoma Court of Criminal Appeals Cases</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=1021">1977 OK CR 65</a>, <a href="DeliverDocument.asp?CiteID=1021">561 P.2d 539</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=1021">WHITEHORN v. STATE</a></font></td><td width="24%" valign="top"><font size="1" color="red">Discussed</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=658">1976 OK CR 29</a>, <a href="DeliverDocument.asp?CiteID=658">546 P.2d 653</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=658">GOODNER v. STATE</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Oklahoma Court of Civil Appeals Cases</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=275952">2001 OK CIV APP 130</a>, <a href="DeliverDocument.asp?CiteID=275952">35 P.3d 1009</a>, <a href="DeliverDocument.asp?CiteID=275952">72 OBJ        3307</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=275952">STATE EX. REL. GIBSON v. 1997 DODGE 350 ONE-TON DUALLY PICKUP</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=468276">2012 OK CIV APP 75</a>, <a href="DeliverDocument.asp?CiteID=468276">290 P.3d 771</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=468276">STATE ex rel. MASHBURN v. $18,007.00</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=548274">2025 OK CIV APP 16</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=548274">SYL OKLAHOMA, LLC et al. v STATE OF OKLAHOMA ex rel. GRUBB</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Oklahoma Supreme Court Cases</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=451409">2008 OK 32</a>, <a href="DeliverDocument.asp?CiteID=451409">184 P.3d 1078</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=451409">STATE ex rel. CAMPBELL v. EIGHTEEN THOUSAND TWO HUNDRED THIRTY-FIVE DOLLARS</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=481711">2017 OK 100</a>, <a href="DeliverDocument.asp?CiteID=481711">408 P.3d 599</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=481711">HUNSUCKER v. FALLIN</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Oklahoma Jury Instructions- Criminal</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"></font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=81332">Introduction, General</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Oklahoma Session Laws - 2000</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=212786">2000 O.S.L. 16</a>, <a href="DeliverDocument.asp?CiteID=212786">2000 O.S.L. 16</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=212786">[SB 1467] - An Act relating to public health and safety; amending 63 O.S. 1991, Section 2-204, (63 O.S. Supp. 1999, Section 2-204), which relates to Schedule I controlled dangerous substances; expanding list, etc.</a></font></td><td width="24%" valign="top"><font size="1" color="red">Discussed at Length</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Title 47. Motor Vehicles</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=439901">47 O.S. 11-902</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=439901">Persons Under the Influence of Alcohol or Other Intoxicating Substance or Combination Thereof</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td colspan="4"><font size="1"><strong>Title 63. Public Health and Safety</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=437011">63 O.S. 2-101</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=437011">Definitions</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=98970">63 O.S. 2-505</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=98970">Summary Forfeiture of Certain Substances</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>


</TBODY>
</TABLE>
<FONT FACE=ARIAL SIZE=2><B><EM>Citationizer: Table of Authority<HR>
</B><FONT FACE=ARIAL SIZE=1>
<TABLE>
<THEAD>
	<TH ALIGN=LEFT><FONT SIZE=1>Cite</FONT></TH>
	<TH ALIGN=LEFT><FONT SIZE=1>Name</FONT></TH>
	<TH ALIGN=LEFT><FONT SIZE=1>Level</FONT></TH>
</THEAD>
<TBODY>
<tr><td colspan="4"><font size="1"><strong>Title 63. Public Health and Safety</strong></font></td></tr>
<tr><td width="1%"><font size="1">&nbsp;</font></td><td width="25%"><font size="1">Cite</font></td><td width="50%"><font size="1">Name</font></td><td wdith="24%"><font size="1">Level</font></td></td></tr>

<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=213838">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=213838">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=264385">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=264385">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=443785">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=443785">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=445666">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=445666">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=453127">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=453127">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=460563">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=460563">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=463733">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=463733">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=467344">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=467344">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=470699">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=470699">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=474234">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=474234">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=476555">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=476555">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=481338">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=481338">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=482888">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=482888">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=485039">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=485039">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=489433">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=489433">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=491243">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=491243">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=494835">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=494835">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=495908">63 O.S. 2-204</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=495908">Schedule I</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>
<tr><td width="1%" valign="top"><font size="1">&nbsp;</font></td><td width="25%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=98863">63 O.S. 2-201</a>, </font></td><td width="50%" valign="top"><font size="1"><a href="DeliverDocument.asp?CiteID=98863">Authority to Control - Recommendations</a></font></td><td width="24%" valign="top"><font size="1" color="red">Cited</font></td></tr>


</TBODY>
</TABLE>
</BODY>
</HTML>


<script>
if(dbCode.indexOf('STOKST')==0){
	// Create new script element
	const formatting_script = document.createElement('script');
	formatting_script.src = '/assets/js/formatting-statutes.js';
	// Append to the `head` element
	document.head.appendChild(formatting_script);
	
	
	// Create new script element
	const hotkeys_script = document.createElement('script');
	hotkeys_script.src = 'https://unpkg.com/hotkeys-js/dist/hotkeys.min.js';

	hotkeys_script.addEventListener('load', function() {
		hotkeys('ctrl+alt+k', function (event, handler){
		  switch (handler.key) {
			case 'ctrl+alt+k':
				if($('.paragraphs').length == 0){ fixlayout(); };
			  break;
			default: alert(event);
		  }
		});
	});
	// Append to the `head` element
	document.head.appendChild(hotkeys_script);
}
</script>
<!-- /CONTENT/ --></div></div>
	<footer id="colophon" class="site-footer fullwidth" data-elastic-exclude>
		<div class="site-info oksc-content">
			<div class="center-brand">
				<a class="oscn-brand" href="/">
					<div class="oscn-brand-container">
						<div class="oscn-logo"><img src="https://www.oscn.net/static/supreme-court-seal-updated-color.svg"></div>
						<div class="oscn-full-name"><span>OKLAHOMA <br>STATE <br>COURTS <br>NETWORK </span></div>
						<div class="oscn-abbreviation"><span>OSCN</span></div>
					</div>
				</a>
			</div>
			<div class="row">
				<div class="col-xs"></div>
				<div class="col-xs" style="text-align: center;">
								
					The Oklahoma Supreme Court<br />
					2100 N. Lincoln Blvd., Suite 1<br />
					Oklahoma City, OK 73105<br />
					<br />
					<br />					
				</div>
				<div class="col-xs"></div>
			</div>
		</div><!-- .site-info -->
	</footer><!-- #colophon -->
	</div>
		<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mustache.js/4.1.0/mustache.min.js?ver=1" id="mustache-js"></script>
        <script src="/assets/js/jquery-1.11.1.min.js"></script>
        <script src="/assets/js/vendor/jquery-cookie.js"></script>		
        <script src="/assets/js/bootstrap.min.js"></script>
		<!--<script src="/assets/js/adobe.aria.menu.min.js"></script>-->
        <!--<script src="/assets/js/navigation.js"></script>-->
        <!--<script src="/assets/js/oscn.js"></script>-->
        <script src="/assets/js/table.sort.filter.js"></script>
<script>
	if (window.NodeList && !NodeList.prototype.forEach) { NodeList.prototype.forEach = Array.prototype.forEach; }
	
	var d = new Date()
	var cb = d.getFullYear().toString() + (d.getMonth()+1).toString() + ("0" + d.getDate()).slice(-2) + d.getHours()
	
	var anchors = document.querySelectorAll("a[href$='.pdf']")
	anchors.forEach(function(a){
		a.href = a.href.split('?')[0] + "?d=" + cb;		
	});
	
</script>
<!--[if IE 7]>
	<script>
		var height = $(".home-banner").height();
		$("#bg").height(height);
	</script>
<![endif]-->    </body>
</html>